# Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects

> **NCT06501586** · PHASE1 · COMPLETED · sponsor: **Suzhou Sanegene Bio Inc.** · enrollment: 40 (actual)

## Conditions studied

- Hypertension,Essential

## Interventions

- **DRUG:** SGB-3908
- **OTHER:** SGB-3908-Matching placebo

## Key facts

- **NCT ID:** NCT06501586
- **Lead sponsor:** Suzhou Sanegene Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-31
- **Primary completion:** 2025-04-07
- **Final completion:** 2025-12-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06501586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06501586, "Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06501586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*